EarningsQ4 2024 Earnings Report

Atossa Therapeutics (ATOS) Q4 2024 Earnings Report

0 Followers

Previous Report: Q3 2024

Next Report: Q1 2025

MX:ATOS Q4 2024 EPS Results

Actual EPS-$11.27

Consensus EPS-$17.85

Beat/MissBeat by +$6.58

One Year Ago EPS-$16.91

MX:ATOS Q4 2024 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ4 2024

Date03/25/2025

TimeBefore Open

Conference CallTuesday, March 25, 2025

MX:ATOS Upcoming Earnings

Atossa Therapeutics's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

Q4 2024 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q4 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2024 Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 25, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.

Company Guidance

In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.

Reduced Operating Expenses

Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.

R&D Cost Reduction

R&D expenses declined by $3.2 million from $17.3 million in 2023 to $14.1 million in 2024, driven by a reduction in clinical and preclinical spending on (Z)-endoxifen trials and drug development.

Strong Cash Position

The company closed the year with $71.1 million in cash and cash equivalents, providing a healthy runway to advance (Z)-endoxifen and other research initiatives.

(Z)-endoxifen Clinical Progress

(Z)-endoxifen showed promising results in Phase I and Phase II studies, demonstrating robust plasma concentration, a 26% clinical benefit rate in difficult-to-treat settings, and significant reduction in mammographic breast density.

Metastatic Breast Cancer Focus

The company is prioritizing the advancement of (Z)-endoxifen in metastatic breast cancer, aiming for a potential expedited approval and faster time to market.

MX:ATOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2026 (Q3)	-16.10 / -	-19.726	―
Aug 07, 2026	2026 (Q2)	-19.26 / -17.85	-19.726	9.52% (+1.88)
May 08, 2026	2026 (Q1)	-18.60 / -20.85	-14.09	-48.00% (-6.76)
Mar 25, 2026	2025 (Q4)	-21.38 / -22.36	-11.272	-98.33% (-11.08)
Nov 12, 2025	2025 (Q3)	-18.32 / -19.73	-16.908	-16.67% (-2.82)
Aug 12, 2025	2025 (Q2)	-16.19 / -19.73	-14.09	-40.00% (-5.64)
May 13, 2025	2025 (Q1)	-15.97 / -14.09	-14.09	0.00% (0.00)
Mar 25, 2025	2024 (Q4)	-17.85 / -11.27	-16.908	33.33% (+5.64)
Nov 12, 2024	2024 (Q3)	-16.91 / -16.91	-14.09	-20.00% (-2.82)
Aug 12, 2024	2024 (Q2)	-16.91 / -14.09	-22.544	37.50% (+8.45)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed